Patient characteristics and demographics
| Characteristic . | Group 1; n = 13 . | Group 2; n = 11 . | Group 3; n = 9 . | All patients; n = 33 . |
|---|---|---|---|---|
| Age, y | ||||
| Median | 65 | 69 | 67 | 67 |
| Range | 37-82 | 26-80 | 49-78 | 26-82 |
| Male, n (%) | 8 (62) | 5 (45) | 5 (56) | 18 (55) |
| White, n (%) | 10 (77) | 7 (64) | 8 (89) | 25 (76) |
| Black, n (%) | 3 (23) | 4 (36) | 1 (11) | 8 (24) |
| Blood involved by FC, n (%) | 8 (62) | 7 (64) | 5 (56) | 20 (61) |
| Sezary syndrome, n (%) | 3 (23) | 4 (36) | 4 (44) | 11 (33) |
| Lymph node involvement, n (%) | 8 (62) | 7 (64) | 4 (44) | 19 (58) |
| Tumor involvement, n (%) | 2 (15) | 1 (9) | 2 (22) | 5 (15) |
| BSA involvement | ||||
| Median | 54 | 38 | 17 | 45 |
| Range | 18-85 | 2-100 | 2-98 | 2-100 |
| Pruritus scores | ||||
| Median | 10 | 6 | 3 | 8 |
| Range | 3-10 | 1-10 | 0-10 | 0-10 |
| CTCL stage, n (%) | ||||
| IA | 0 (0) | 0 (0) | 1 (11) | 1 (3) |
| IB | 1 (8) | 1 (9) | 1 (11) | 3 (9) |
| IIA | 1 (8) | 0 (0) | 0 (0) | 1 (3) |
| IIB | 2 (15) | 1 (9) | 2 (22) | 5 (15) |
| III | 1 (8) | 2 (18) | 2 (22) | 5 (15) |
| IVA | 5 (38) | 4 (36) | 1 (11) | 10 (30) |
| IVB | 3 (23) | 3 (27) | 2 (22) | 8 (24) |
| Time from CTCL diagnosis, y | ||||
| Median | 3.7 | 3.1 | 2.7 | 3.3 |
| Range | 0.4-17.4 | 1.1-27.2 | 0.2-15.0 | 0.2-27.2 |
| Prior systemic treatments | ||||
| Median | 5 | 5 | 4 | 5 |
| Range | 1-10 | 2-15 | 1-9 | 1-15 |
| Prior chemotherapy, n (%) | 11 (85) | 10 (91) | 8 (89) | 29 (88) |
| Prior bexarotene, n (%) | 9 (69) | 7 (64) | 6 (67) | 22 (67) |
| Prior denileukin diftitox, n (%) | 5 (39) | 6 (55) | 3 (33) | 14 (42) |
| Prior photopheresis*, n (%) | 9 (69) | 5 (45) | 5 (56) | 19 (58) |
| Characteristic . | Group 1; n = 13 . | Group 2; n = 11 . | Group 3; n = 9 . | All patients; n = 33 . |
|---|---|---|---|---|
| Age, y | ||||
| Median | 65 | 69 | 67 | 67 |
| Range | 37-82 | 26-80 | 49-78 | 26-82 |
| Male, n (%) | 8 (62) | 5 (45) | 5 (56) | 18 (55) |
| White, n (%) | 10 (77) | 7 (64) | 8 (89) | 25 (76) |
| Black, n (%) | 3 (23) | 4 (36) | 1 (11) | 8 (24) |
| Blood involved by FC, n (%) | 8 (62) | 7 (64) | 5 (56) | 20 (61) |
| Sezary syndrome, n (%) | 3 (23) | 4 (36) | 4 (44) | 11 (33) |
| Lymph node involvement, n (%) | 8 (62) | 7 (64) | 4 (44) | 19 (58) |
| Tumor involvement, n (%) | 2 (15) | 1 (9) | 2 (22) | 5 (15) |
| BSA involvement | ||||
| Median | 54 | 38 | 17 | 45 |
| Range | 18-85 | 2-100 | 2-98 | 2-100 |
| Pruritus scores | ||||
| Median | 10 | 6 | 3 | 8 |
| Range | 3-10 | 1-10 | 0-10 | 0-10 |
| CTCL stage, n (%) | ||||
| IA | 0 (0) | 0 (0) | 1 (11) | 1 (3) |
| IB | 1 (8) | 1 (9) | 1 (11) | 3 (9) |
| IIA | 1 (8) | 0 (0) | 0 (0) | 1 (3) |
| IIB | 2 (15) | 1 (9) | 2 (22) | 5 (15) |
| III | 1 (8) | 2 (18) | 2 (22) | 5 (15) |
| IVA | 5 (38) | 4 (36) | 1 (11) | 10 (30) |
| IVB | 3 (23) | 3 (27) | 2 (22) | 8 (24) |
| Time from CTCL diagnosis, y | ||||
| Median | 3.7 | 3.1 | 2.7 | 3.3 |
| Range | 0.4-17.4 | 1.1-27.2 | 0.2-15.0 | 0.2-27.2 |
| Prior systemic treatments | ||||
| Median | 5 | 5 | 4 | 5 |
| Range | 1-10 | 2-15 | 1-9 | 1-15 |
| Prior chemotherapy, n (%) | 11 (85) | 10 (91) | 8 (89) | 29 (88) |
| Prior bexarotene, n (%) | 9 (69) | 7 (64) | 6 (67) | 22 (67) |
| Prior denileukin diftitox, n (%) | 5 (39) | 6 (55) | 3 (33) | 14 (42) |
| Prior photopheresis*, n (%) | 9 (69) | 5 (45) | 5 (56) | 19 (58) |
BSA indicates body surface area; CTCL, cutaneous T-cell lymphoma; FC, flow cytometry.
Patients also received a combination of low-dose biologic response modifiers.